Hormone Resistant Prostate Cancer Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgenindependent prostate cancer cells to DNA damage.
Authors: Marampon F, Gravina GL, Ju X, Vetuschi A, Sferra R, Casimiro MC, Pompili S, Festuccia C, Colapietro A, Gaudio E, Di Cesare E, Tombolini V, Pestell RG Abstract Patients with hormone-resistant prostate cancer (PCa) have higher biochemical failure rates following radiation therapy (RT). Cyclin D1 deregulated expression in PCa is associated with a more aggressive disease: however its role in radioresistance has not been determined. Cyclin D1 levels in the androgen-independent PC3 and 22Rv1 PCa cells were stably inhibited by infecting with cyclin D1-shRNA. Tumorigenicity and radiosensitivity were inves...
Source: Oncotarget - December 26, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

AMPK in TRAIL Combination-induced Apoptosis [Signal Transduction]
Prostate cancer (PCa) is one of the most frequently diagnosed cancers in men with limited treatment options for the hormone-resistant forms. Development of novel therapeutic options is critically needed to target advanced forms. Here we demonstrate that combinatorial treatment with the thiazolidinedione troglitazone (TZD) and TNF-related apoptosis-inducing ligand (TRAIL) can induce significant apoptosis in various PCa cells independent of androgen receptor status. Because TZD is known to activate AMP-activated protein kinase (AMPK), we determined whether AMPK is a molecular target mediating this apoptotic cascade by utiliz...
Source: Journal of Biological Chemistry - September 4, 2015 Category: Chemistry Authors: Santha, S., Viswakarma, N., Das, S., Rana, A., Rana, B. Tags: Cell Biology Source Type: research

Abstract 4995: HO1 induction interrupts the glucocorticoid receptor signaling in prostate cancer cells
Although initially treatable, prostate cancer can recur in a hormone refractory form that is not responsive to current available therapies. The mortality rate associated with hormone refractory prostate cancer is high, and there is an urgent need for new therapeutic agents to treat prostate cancer. In order to overcome the toxicity of chemotherapy, glucocorticoids have long been used in the treatment of hormone-resistant prostate cancer. Nevertheless, many authors reported that the glucocorticoid receptor (GR) can substitute the androgen receptor and activate a similar but distinguishable set of genes. A common feature of ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Leonardi, D. B., Paez, A. V., Schuster, F., Anselmino, N., Brandani, J. N., Abbate, M., Gueron, G., Cotignola, J. H., Vazquez, E. S. Tags: Molecular and Cellular Biology Source Type: research

Abstract 1790: Caloric restriction can increase the efficacy of radiation in both hormone-sensitive and hormone-resistant prostate cancers by downregulating the IGF-1R pathway
Locally advanced prostate cancers (LAPC) are aggressive, have poor prognosis, and are associated with high recurrence rates and conversion to castrate resistance. The molecular underpinnings of LAPC are being investigated to identify novel therapeutics. Animal models have shown that caloric restriction (CR) can potentially prevent the initiation of prostate cancer. We propose that CR may be used as a novel therapeutic intervention to enhance outcomes of radiation treatment by altering the molecular profile of prostate tumors.To assess the effect of CR with radiation in vivo, eighty 6 week old male nude mice were injected w...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Han, S. Y., Dan, T. D., De Angelis, T., Han, J. Y., Sarich, M., Carroll, P., Knudsen, K., Dicker, A., Simone, N. L. Tags: Experimental and Molecular Therapeutics Source Type: research

[Molecular biology of castration-resistant prostate cancer].
Abstract Castration-resistant prostate cancer was subjected to a paradigm switch from hormone resistance to androgen deprivation therapy resistance during the last decade. Indeed, new therapeutics targeting the androgen receptor showed clinical efficacy in patients with progressive disease under castration. Thus, it is a proof that the AR remains a dominant driver of oncogenesis in earlier-called hormone resistant prostate cancer. This review summarizes the molecular mechanisms involved in castration-resistant prostate cancer. PMID: 26028493 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 28, 2015 Category: Cancer & Oncology Authors: Doucet L, Terrisse S, Gauthier H, Pouessel D, Le Maignan C, Teixeira L, Culine S Tags: Bull Cancer Source Type: research

The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.
Abstract Although ErbB receptors have been implicated in prostate cancer progression, ErbB-directed drugs have not proven effective for prostate cancer treatment. The ErbB3-binding protein EBP1 affects both ErbB2 and androgen receptor signaling, two components of the response to ErbB-targeted therapies. We therefore examined the effects of EBP1 expression on the response to the ErbB1/2 tyrosine kinase inhibitor lapatinib. We found a negative correlation between endogenous EBP1 levels and lapatinib sensitivity in prostate cancer cell lines. We then overexpressed or inhibited expression of EBP1. Silencing EB...
Source: Molecular and Cellular Biochemistry - April 17, 2015 Category: Biochemistry Authors: Awasthi S, Ezelle H, Hassel BA, Hamburger AW Tags: Mol Cell Biochem Source Type: research

Effects of zoledronic acid and docetaxel on small GTP-binding proteins in prostate cancer
Abstract Increasingly, in castration-resistant prostate cancer, patients are often treated with docetaxel and the bisphosphonate zoledronic acid concurrently, yet there is still a paucity in the literature regarding the molecular basis of how this drug combination works. The study was performed on the hormone-resistant cell line PC-3. Cells were treated with clinically relevant concentrations of docetaxel and zoledronic acid either as single agents or in sequence and combination. Cell viability and apoptosis were assessed along with the prenylation status of the GTPases Ras and RhoA. Following 1-mM zoledr...
Source: Tumor Biology - January 29, 2015 Category: Cancer & Oncology Source Type: research

NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect.
In conclusion, NCL1 effectively suppressed prostate cancer growth without adverse events. We suggest that NCL1 is a potential therapeutic agent for hormone-resistant prostate cancer. PMID: 25605246 [PubMed - as supplied by publisher] (Source: Oncotarget)
Source: Oncotarget - January 27, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Editorial Comment
This study1 looked into predictors of developing symptomatic local progression in a subset of men diagnosed with prostate cancer and treated with primary hormonal therapy. (Source: Urology)
Source: Urology - January 24, 2015 Category: Urology & Nephrology Authors: Sergey Shikanov Tags: Oncology Source Type: research

Wine polyphenols exert antineoplasic effect on androgen resistant PC-3 cell line through the inhibition of the transcriptional activity of COX-2 promoter mediated by NF-κβ
Conclusions Polyphenols inhibit transcriptional activity of COX-2 promoter mediated by NF-κβ. This effect could explain, at least in part, the induction of apoptosis in vitro by these substances in castration resistant PCa. (Source: Actas Urologicas Espanolas)
Source: Actas Urologicas Espanolas - October 22, 2014 Category: Urology & Nephrology Source Type: research

Induction of Apoptosis in Hormone-resistant Human Prostate Cancer PC3 Cells by Inactivated Sendai Virus
Conclusion Our findings have provided novel insights into the underlying mechanisms by which HVJ-E induces apoptosis in tumor cells. (Source: Biomedical and Environmental Sciences)
Source: Biomedical and Environmental Sciences - October 12, 2014 Category: Biomedical Science Source Type: research

[Editorial] Emotion-based medicine or evidence-based medicine?
The UK National Institute for Health and Care Excellence (NICE) is once again under the microscope because of recent recommendations for various cancer drugs. In the past 2 months, just one recommendation out of four has been positive. Nab-paclitaxel for metastatic pancreatic cancer (Sept 8, 2014); trastuzumab emtansine for HER2-positive breast cancer (Aug 7, 2014); and abiraterone for metastatic, hormone-resistant prostate cancer (Aug 14, 2014) have all been rejected on the grounds of insufficient cost-effectiveness. (Source: The Lancet Oncology)
Source: The Lancet Oncology - October 1, 2014 Category: Cancer & Oncology Authors: The Lancet Oncology Tags: Editorial Source Type: research

480p * phase ii, multicenter, open-label, proof of concept study of tasquinimod in patients with advanced hepatocellular (hcc), ovarian (oc), renal cell (rcc) and gastric (gc) carcinomas
Conclusions: The data did not support further development of tasquinimod mono therapy in heavily pretreated patients with OC, RCC and GC. Pharmacokinetic and biomarkers analyses are ongoing.HCC cohort is continuing with results expected 2015.Pili R et al, J Clin Oncol. 2011; 29:4022-8.Escudier B et al, J Clin Oncol. 2013;31(abstract TPS2622).Disclosure: R. Plummer: Ipsen funding to institution for present study; I.B. Vergote: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Eisai, Eli Lilly, GE, GSK, Ipsen, Janssen, Menarini, MSD, Novartis, Novo Nordisk, Pfizer, Quintiles, Roche, Sanofi, Sandoz, Sher...
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Oza, A. M., Plummer, R., Vergote, I. B., Thistlethwaite, F., Bjarnason, G. A., Jones, R. J., Mackay, H., Van Cutsem, E., Faivre, S., Descot, C., Germann, N., Escudier, B. Tags: developmental therapeutics Source Type: research

The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness.
Conclusions: Loss of RB confers increased radiosensitivity in prostate cancer. This hypersensitization was mediated by alterations in apoptotic signaling. Combined, these not only provide insight into the molecular consequence of RB loss, but also credential RB status as a putative biomarker for predicting response to radiation therapy. PMID: 25165096 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - August 27, 2014 Category: Cancer & Oncology Authors: Thangavel C, Boopathi E, Ciment S, Liu Y, O'Neill R, Sharma A, McMahon SB, Mellert H, Addya S, Ertel A, Birbe R, Fortina P, Dicker AP, Knudsen KE, Den R Tags: Clin Cancer Res Source Type: research

Induction of Apoptosis in Hormone-resistant Human Prostate Cancer PC3 Cells by Inactivated Sendai Virus.
CONCLUSION: Our findings have provided novel insights into the underlying mechanisms by which HVJ-E induces apoptosis in tumor cells. PMID: 25073909 [PubMed - in process] (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 1, 2014 Category: Biomedical Science Authors: Gao H, Gong XC, Chen ZD, Xu XS, Zhang Q, Xu XM Tags: Biomed Environ Sci Source Type: research